Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial
Details
Publication Year 2024-09,Volume 30,Issue #9,Page 2540-2548
Journal Title
Nature Medicine
Abstract
Immune checkpoint inhibitors and BRAF-targeted therapy each improve survival in melanoma. Immune changes early during targeted therapy suggest the mechanisms of each drug class could work synergistically. In the non-comparative, randomized, phase 2 NeoTrio trial, we investigated whether targeted therapy could boost the proportion of patients achieving long-term recurrence-free survival with neoadjuvant immunotherapy in resectable stage III BRAF(V600)-mutant melanoma. Sixty patients (42% females) were randomized to pembrolizumab alone (n = 20), sequential therapy (dabrafenib plus trametinib followed by pembrolizumab; n = 20) or concurrent (triple) therapy (n = 20), followed by surgery and adjuvant therapy. The primary outcome was pathological response; secondary outcomes included radiographic response, recurrence-free survival, overall survival, surgical outcomes, peripheral blood and tumor analyses and safety. The pathological response rate was 55% (11/20; including six pathological complete responses (pCRs)) with pembrolizumab, 50% (10/20; three pCRs) with sequential therapy and 80% (16/20; ten pCRs) with concurrent therapy, which met the primary outcome in each arm. Treatment-related adverse events affected 75-100% of patients during neoadjuvant treatment, with seven early discontinuations (all in the concurrent arm). At 2 years, event-free survival was 60% with pembrolizumab, 80% with sequential therapy and 71% with concurrent therapy. Recurrences after major pathological response were more common in the targeted therapy arms, suggesting a reduction in response 'quality' when targeted therapy is added to neoadjuvant immunotherapy. Risking the curative potential of immunotherapy in melanoma cannot be justified. Pending longer follow-up, we suggest that immunotherapy and targeted therapy should not be combined in the neoadjuvant setting for melanoma. ClinicalTrials.gov registration: NCT02858921 .
Keywords
Humans; *Melanoma/drug therapy/genetics/pathology; *Antibodies, Monoclonal, Humanized/therapeutic use/administration &; dosage/adverse effects; *Pyrimidinones/therapeutic use/administration & dosage; *Pyridones/therapeutic use/administration & dosage; *Proto-Oncogene Proteins B-raf/genetics; Female; Male; *Neoadjuvant Therapy; Middle Aged; *Oximes/administration & dosage/therapeutic use; Aged; *Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Adult; *Imidazoles/therapeutic use/administration & dosage; *Mutation; Immunotherapy/methods
Department(s)
Surgical Oncology
Open Access at Publisher's Site
https://doi.org/10.1038/s41591-024-03077-5
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-10-01 05:05:39
Last Modified: 2024-10-01 05:05:56

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙